Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE study of AZD4547 versus paclitaxel in FGFR2-amplified advanced gastric or gastro-oesophageal adenocarcinoma
2010-023377-19Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma comparing AZD4547 monotherapy with Paclitaxel monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Aug 2011; status: completed.
02
Drugs
fexagratinibpaclitaxel
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2010-023377-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023377-19.